Dyadic Faces Two Nasdaq Delisting Notices Over Bid Price and Market Value Shortfalls
DYAI sits 23% above its 52-week low of $0.34.
Summary
Dyadic received two Nasdaq deficiency notices on September 25, 2026 for failing to maintain a $1 minimum bid price and a $35 million minimum market value. The company has until March 24, 2027 to regain compliance.
Key Events · Legal and Risk Events · DYAI
-
Two Nasdaq Delisting Notices Received
Dyadic received deficiency notices for failing to maintain a $1 minimum bid price and a $35 million minimum market value of listed securities, each for 30 consecutive business days.
-
Compliance Deadline Set for March 24, 2027
The company has 180 calendar days to regain compliance with both requirements, with a possible second 180-day extension if it meets certain conditions.
-
Reverse Stock Split Likely Under Consideration
With the stock trading at $0.42, the company will likely need a reverse stock split to regain the $1 minimum bid price, as explicitly referenced in the filing.
-
Going Concern Context
This delisting risk compounds the going concern warning disclosed in Dyadic's Q2 2026 10-Q filed August 12, 2026, when cash reserves were $4.8 million.
Analysis · DYAI · Life Sciences
On September 25, 2026, Dyadic received two separate Nasdaq deficiency notices: one for failing to maintain a $1 minimum bid price and another for failing to maintain a $35 million minimum market value of listed securities. Both give the company until March 24, 2027 to regain compliance. This comes just weeks after the company regained compliance with Nasdaq listing rules in July 2026 and amid a going concern warning from its Q2 2026 filing. The stock now trades at $0.42, far below the $1 threshold, making a reverse stock split a likely remedy. Delisting would severely impair liquidity and access to capital for a company already burning cash.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 46% of the 298 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYAI was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7M. The 52-week trading range was $0.34 to $1.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.